Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
The company’s claims of a win with its cervical precancer therapy candidate look questionable.
Trial results in Covid-19 and cancer emerge, but little promise is seen.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.